(Q43554157)

English

Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

based on heuristic

inferred from title

author name string

Fayer JL

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Zannikos PN

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Stevens JC

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Luo Y

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sidhu R

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Kirkesseli S

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2001

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

305-316

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

In vitro approaches to predicting drug interactions in vivo.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Fatal interaction between ritonavir and MDMA

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Metabolic drug-drug interactions: perspective from FDA medical and clinical pharmacology reviewers.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010122

21 January 2018

Identifiers

10.1177/00912700122010122

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43554157&oldid=2100732668"